Paclitaxel treatment reduces neointimal hyperplasia in cultured human saphenous veins

Thomas Schachner1, Christina Steger, Simone Heiss

  • 1Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria. Thomas.Schachner@i-med.ac.at

Abstract

Insights

Paclitaxel treatment significantly reduced neointimal hyperplasia in cultured human saphenous veins. This finding suggests paclitaxel

Area of Science:

  • Vascular Biology
  • Pharmacology
  • Regenerative Medicine

Background:

  • Paclitaxel stabilizes microtubules and is used in drug-eluting coronary stents.
  • Neointimal hyperplasia is a significant issue in vein grafts after coronary artery bypass grafting (CABG).

Purpose of the Study:

  • To investigate the hypothesis that paclitaxel can reduce neointimal hyperplasia in cultured human saphenous veins.
  • To evaluate paclitaxel's potential for local pharmacologic treatment of vein grafts before CABG.

Main Methods:

  • Human saphenous veins from 13 CABG patients were cultured for 2 weeks to induce neointimal hyperplasia.
  • Paclitaxel was added to the culture medium at varying concentrations (1, 10, 25, 50 µmol/l).
  • Neointimal thickness, smooth muscle actin (SMA), desmin, ki-67, elastic, and collagen fibers were analyzed.

Main Results:

  • 1 µmol/l paclitaxel reduced intimal thickness increase to 2 µm (vs. 15 µm in controls, p=0.022).
  • 10 µmol/l paclitaxel further reduced intimal thickness increase to 1 µm (p=0.035 vs. controls).
  • Higher paclitaxel concentrations did not show further inhibition; SMA levels increased significantly in treated veins (p=0.037).

Conclusions:

  • Local paclitaxel treatment effectively reduces neointimal hyperplasia in cultured human saphenous veins.
  • Paclitaxel treatment increased smooth muscle actin (SMA) levels without altering elastic or collagen fibers.
  • Paclitaxel demonstrates therapeutic potential for preventing vein graft disease.

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Varicose Veins II: Diagnostic Studies and Interprofessional Care01:26

Varicose Veins II: Diagnostic Studies and Interprofessional Care

Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...